CD1a antibody-expressing CAR T-cells for the treatment of CD1a-positive cancer

A method of treating a CD 1a-positive cancer in a subject in need thereof, said method comprising administering to said subject a CD1a-negative allo-tolerant T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR) comprising:

• (i) an extracellular domain comprising a CD 1a targeting-moiety, wherein the CD 1a targeting moiety is an antibody, scFv, Fab, or scFab comprising a VL domain and VH domain,
• wherein said VL domain comprises LCDR1, LCDR2 and LCDR3 polypeptides and said VH domain comprises HCDR1, HCDR2 and HCDR3 polypeptides, and LCDR1 consists of QDINKY (SEQ ID NO:
• 1), LCDR2 consists of YTS, LCDR3 consists of LHYDNLPWT (SEQ ID NO:
• 3), HCDR1 consists of GYAFSTYT (SEQ ID NO:
• 4), HCDR2 consists of INPNSAST (SEQ ID NO:
• 5), and HCDR3 consists of ARGFYTMDY (SEQ ID NO:
• 6);
• (ii) a transmembrane domain;
• and
• (iii) an intracellular signaling domain.